Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

Fig. 2

Median plasma concentration-time profile of SAD of PF-06650833 a IR doses ≤ 100 mg, b IR doses > 100 mg, and c MR formulations. All doses were administered orally under fasting conditions (overnight fast of ≥ 10 h) unless otherwise indicated. Fed doses were administered after consumption of a high-fat breakfast meal. Summary statistics were calculated by setting concentration values below the LLOQ to 0. The LLOQ was 0.0500 ng/mL. IR immediate-release; LLOQ lower limit of quantification; MR modified-release; SAD single ascending doses

Back to article page